PURPOSE: The purpose of this study was to describe inhaled colistin pharmacokinetics in patients with ventilator-associated tracheobronchitis (VAT) due to polymyxin-only susceptible Gram-negative bacteria (GNB). METHODS: Inhaled colistimethate sodium (CMS) was administered at a dose of 80 mg every 8 h for 7 days. Mini bronchoalveolar lavage (BAL) was performed before and at 1, 4 and 8 h, while blood samples were collected before and at 0.16, 0.5, 1, 2, 4 and 8 h after the first dose. Colistin concentrations in BAL and serum were determined by high-performance liquid chromatography. RESULTS: Our study population included 20 patients. At the end of treatment, cure was achieved in 16 patients and favorable microbiological response in 12 patients. Median (25-75 % interquartile range) colistin concentrations in epithelial lining fluid (ELF) were 6.7 (4.8-10.1), 3.9 (2.5-6.0) and 2.0 (1.0-3.8) μg/ml at 1, 4 and 8 h, respectively, and fivefold higher than those achieved in serum. Median ELF concentrations at 1 and 4 h were above the minimum inhibitory concentrations of all isolated pathogens; however, the 4-h median was below the European Committee on Antimicrobial Susceptibility Guidelines (EUCAST) breakpoints for Pseudomonas aeruginosa and the 8-h median was low relative to EUCAST breakpoints for all GNB. Colistin pharmacokinetic/pharmacodynamic parameters in ELF were associated with favorable microbiological response at the end of treatment. CONCLUSION: Inhaled colistin may achieve high drug concentrations in the lung. However, a dose of 80 mg of inhaled CMS every 8 h may not be adequate for the treatment of lower respiratory tract infections due to multi-drug resistant GNB.
PURPOSE: The purpose of this study was to describe inhaled colistin pharmacokinetics in patients with ventilator-associated tracheobronchitis (VAT) due to polymyxin-only susceptible Gram-negative bacteria (GNB). METHODS: Inhaled colistimethate sodium (CMS) was administered at a dose of 80 mg every 8 h for 7 days. Mini bronchoalveolar lavage (BAL) was performed before and at 1, 4 and 8 h, while blood samples were collected before and at 0.16, 0.5, 1, 2, 4 and 8 h after the first dose. Colistin concentrations in BAL and serum were determined by high-performance liquid chromatography. RESULTS: Our study population included 20 patients. At the end of treatment, cure was achieved in 16 patients and favorable microbiological response in 12 patients. Median (25-75 % interquartile range) colistin concentrations in epithelial lining fluid (ELF) were 6.7 (4.8-10.1), 3.9 (2.5-6.0) and 2.0 (1.0-3.8) μg/ml at 1, 4 and 8 h, respectively, and fivefold higher than those achieved in serum. Median ELF concentrations at 1 and 4 h were above the minimum inhibitory concentrations of all isolated pathogens; however, the 4-h median was below the European Committee on Antimicrobial Susceptibility Guidelines (EUCAST) breakpoints for Pseudomonas aeruginosa and the 8-h median was low relative to EUCAST breakpoints for all GNB. Colistin pharmacokinetic/pharmacodynamic parameters in ELF were associated with favorable microbiological response at the end of treatment. CONCLUSION: Inhaled colistin may achieve high drug concentrations in the lung. However, a dose of 80 mg of inhaled CMS every 8 h may not be adequate for the treatment of lower respiratory tract infections due to multi-drug resistant GNB.
Authors: I P Korbila; A Michalopoulos; P I Rafailidis; D Nikita; G Samonis; M E Falagas Journal: Clin Microbiol Infect Date: 2009-09-02 Impact factor: 8.067
Authors: Doo Ryeon Chung; Jae-Hoon Song; So Hyun Kim; Visanu Thamlikitkul; Shao-Guang Huang; Hui Wang; Thomas Man-Kit So; Rohani M D Yasin; Po-Ren Hsueh; Celia C Carlos; Li Yang Hsu; Latre Buntaran; M K Lalitha; Min Ja Kim; Jun Yong Choi; Sang Il Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck Journal: Am J Respir Crit Care Med Date: 2011-09-15 Impact factor: 21.405
Authors: Arzu Ari; Orcin Telli Atalay; Robert Harwood; Meryl M Sheard; Essam A Aljamhan; James B Fink Journal: Respir Care Date: 2010-07 Impact factor: 2.258
Authors: Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi Journal: Chest Date: 2010-06-17 Impact factor: 9.410
Authors: D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou Journal: Antimicrob Agents Chemother Date: 2009-05-11 Impact factor: 5.191
Authors: Emmanuel Boselli; Dominique Breilh; Sarah Djabarouti; Christian Guillaume; Thomas Rimmelé; Jean-Baptiste Gordien; Fabien Xuereb; Marie-Claude Saux; Bernard Allaouchiche Journal: Intensive Care Med Date: 2007-05-25 Impact factor: 17.440
Authors: Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2015-05 Impact factor: 6.447
Authors: Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Shalini Yapa; Jian Li; Kashyap Patel; John W Wilson; Michael J Dooley; Johnson George; Denise Clark; Susan Poole; Elyssa Williams; Christopher J H Porter; Roger L Nation; Michelle P McIntosh Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191